Mizuki Nishino

List of Publications by Year in descending order

154 papers	11,727 citations	44069 48 h-index	30922 102 g-index
155 all docs	155 docs citations	155 times ranked	13287 citing authors

#	Article	IF	Citations
1	Interstitial Lung Abnormalities, Emphysema, and Spirometry in Smokers. Chest, 2022, 161, 999-1010.	0.8	8
2	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. Journal of Thoracic Oncology, 2022, 17, 399-410.	1.1	151
3	Interstitial lung abnormalities are associated with decreased mean telomere length. European Respiratory Journal, 2022, 60, 2101814.	6.7	8
4	Radiomics-based Cluster Groups to Predict Clinical-Pathologic and Genomic Characteristics of Stage I Lung Adenocarcinoma. Radiology, 2022, , 213015.	7.3	0
5	Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma. Journal of Thoracic Oncology, 2022, 17, 779-792.	1.1	50
6	Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)â€“related interstitial lung disease/pneumonitisâ€”Focus on proactive monitoring, diagnosis, and management. Cancer Treatment Reviews, 2022, 106, 102378.	7.7	60
7	Traction Bronchiectasis/Bronchiolectasis on CT Scans in Relationship to Clinical Outcomes and Mortality: The COPDGene Study. Radiology, 2022, 304, 694-701.	7.3	13
8	Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, 9021-9021.	1.6	1
9	Association of High Tumor Mutation Burden in Nonâ€“Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncology, 2022, 8, 1160.	7.1	117
10	Three-year outcomes and correlative analyses in patients with nonâ€“small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) â‰¥ 90% treated with first-line pembrolizumab.. Journal of Clinical Oncology, 2022, 40, 9043-9043.	1.6	3
11	The Association of Aging Biomarkers, Interstitial Lung Abnormalities, and Mortality. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1149-1157.	5.6	35
12	Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-associated Interstitial Lung Disease. Journal of Rheumatology, 2021, 48, 656-663.	2.0	52
13	Dynamic Chest X-Ray Using a Flat-Panel Detector System: Technique and Applications. Korean Journal of Radiology, 2021, 22, 634.	3.4	22
14	BRAF-Mutant Pulmonary Langerhans Cell Histiocytosis Mimicking Recurrence of Early-Stage KRAS-Mutant Lung Adenocarcinoma. JTO Clinical and Research Reports, 2021, 2, 100127.	1.1	2
15	Imaging of Oncologic Treatment-Related Pneumonitis: A Focused Review on Emerging Issues of Immune-Checkpoint Inhibitor Pneumonitis, From the AJR Special Series on Inflammation. American Journal of Roentgenology, 2021, , 1-9.	2.2	7
16	Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2021, 5, 501-509.	3.0	4
17	Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. Radiology, 2021, 298, 550-566.	7.3	53
18	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors. Chest, 2021, 159, 1107-1125.	0.8	53

#	Article	IF	Citations
19	DNMT3A mutation to identify a subset of non-small cell lung cancers with increased sensitivity to PD-(L)1 blockade.. Journal of Clinical Oncology, 2021, 39, 9113-9113.	1.6	2
20	Clinicopathologic and genomic correlates of tumor-infiltrating immune cells and immunotherapy efficacy in NSCLC.. Journal of Clinical Oncology, 2021, 39, 9121-9121.	1.6	2
21	Clinicopathologic, genomic, and tumor microenvironment correlates of aneuploidy and immunotherapy outcomes in NSCLC.. Journal of Clinical Oncology, 2021, 39, 9119-9119.	1.6	0
22	Chronic immune checkpoint inhibitor (ICI) pneumonitis in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2021, 39, 9103-9103.	1.6	0
23	Management of Pulmonary Nodules in Oncologic Patients: AJR Expert Panel Narrative Review. American Journal of Roentgenology, 2021, 216, 1423-1431.	2.2	7
24	SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. Journal of Thoracic Oncology, 2021, 16, 1176-1187.	1.1	49
25	Axillary Lymphadenopathy After Coronavirus Disease 2019 Vaccinations in Patients With Thoracic Malignancy: Incidence, Predisposing Factors, and Imaging Characteristics. Journal of Thoracic Oncology, 2021, , .	1.1	21
26	Prediction Model for Tumor Volume Nadir in EGFR-mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Imaging, 2021, Publish Ahead of Print, .	1.5	0
27	Diagnosis Please Certificates of Recognition Awarded to Four Individuals and to International and North American Radiology Resident Groups. Radiology, 2021, 301, 497-501.	7.3	0
28	Tumor Growth Rate After Nadir Is Associated With Survival in Patients With EGFR-Mutant Nonâ€“Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. JCO Precision Oncology, 2021, 5, 1603-1610.	3.0	4
29	Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. , 2021, 9, e003536.		45
30	Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinaseâ€“rearranged Advanced Nonâ€“Small Cell Lung Cancer Patients Treated With Crizotinib. Journal of Thoracic Imaging, 2020, 35, 101-107.	1.5	7
31	Diagnosis Please Certificates of Recognition Awarded to Five Individuals and to International and North American Radiology Resident Groups. Radiology, 2020, 297, 247-250.	7.3	0
32	Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. European Journal of Radiology, 2020, 132, 109275.	2.6	13
33	Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. Radiology, 2020, 297, 87-96.	7.3	70
34	Outcomes to first-line pembrolizumab in patients with PD-L1-high (â‰¥50%) nonâ€“small cell lung cancer and a poor performance status. , 2020, 8, e001007.		36
35	CT Volumetry for Lung-RADS Classification of Solid Nodules. Radiology, 2020, 297, 685-686.	7.3	2
36	Radiomics to Predict Invasiveness of Part-Solid Adenocarcinoma of the Lung. Radiology, 2020, 297, 459-461.	7.3	3

#	Article	IF	Citations
37	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 4135-4142.	7.0	95
38	Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib. European Journal of Radiology Open, 2020, 7, 100210.	1.6	4
39	Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e435-e444.	2.6	46
40	The Associations of Interstitial Lung Abnormalities with Cancer Diagnoses and Mortality. European Respiratory Journal, 2020, 56, 1902154.	6.7	24
41	Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14â€“Mutant NSCLC. Clinical Cancer Research, 2020, 26, 2615-2625.	7.0	129
42	Radiographic patterns of symptomatic radiation pneumonitis in lung cancer patients: Imaging predictors for clinical severity and outcome. Lung Cancer, 2020, 145, 132-139.	2.0	20
43	Projected lung areas using dynamic X-ray (DXR). European Journal of Radiology Open, 2020, 7, 100263.	1.6	14
44	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. JTO Clinical and Research Reports, 2020, 1, 100074.	1.1	10
45	Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status.. Journal of Clinical Oncology, 2020, 38, e15113-e15113.	1.6	7
46	Drug Toxicity, Approach to Cancer as a Systemic Disease, and Imaging Modality-Specific Considerations. Medical Radiology, 2020, , 31-43.	0.1	0
47	Outcomes to first-line pembrolizumab in patients with PD-L1-high (â‰¥50%) non-small-cell lung cancer and a poor performance status.. Journal of Clinical Oncology, 2020, 38, 9568-9568.	1.6	0
48	Response Evaluations for Precision Cancer Therapy and Immunotherapy. Medical Radiology, 2020, , 15-27.	0.1	0
49	Therapy Response Imaging in Thoracic Malignancy. Medical Radiology, 2020, , 79-97.	0.1	0
50	Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14â€“Mutant NSCLC. JTO Clinical and Research Reports, 2020, 1, 100072.	1.1	4
51	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. Radiology, 2019, 293, 15-29.	7.3	45
52	Using CT to Evaluate Visceral Pleural Invasion: Caution Is Advised. Radiology, 2019, 292, 750-751.	7.3	2
53	Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1402-1413.	5.6	77
54	Diagnosis Please Certificates of Recognition Awarded to Three Individuals and to International and North American Radiology Resident Groups. Radiology, 2019, 293, 241-244.	7.3	0

#	Article	IF	Citations
55	M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome. Oncologist, 2019, 24, e749-e754.	3.7	5
56	Imaging Patterns Are Associated with Interstitial Lung Abnormality Progression and Mortality. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 175-183.	5.6	142
57	Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome. European Journal of Radiology Open, 2019, 6, 128-131.	1.6	23
58	Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. , 2019, 7, 112.		69
59	The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis. Lung Cancer, 2019, 132, 79-86.	2.0	28
60	Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. , 2019, 7, 87.		60
61	Time-resolved quantitative evaluation of diaphragmatic motion during forced breathing in a health screening cohort in a standing position: Dynamic chest phrenicography. European Journal of Radiology, 2019, 113, 59-65.	2.6	22
62	Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritisâ€“Associated Interstitial Lung Disease: A Prospective Cohort Study. Arthritis and Rheumatology, 2019, 71, 1472-1482.	5.6	129
63	Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. Abdominal Radiology, 2019, 44, 1917-1927.	2.1	37
64	Decreased and slower diaphragmatic motion during forced breathing in severe COPD patients: Time-resolved quantitative analysis using dynamic chest radiography with a flat panel detector system. European Journal of Radiology, 2019, 112, 28-36.	2.6	33
65	Measurement Variability in Treatment Response Determination for Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Imaging, 2019, 34, 103-115.	1.5	14
66	Perinodular Radiomic Features to Assess Nodule Microenvironment: Does It Help to Distinguish Malignant versus Benign Lung Nodules?. Radiology, 2019, 290, 793-795.	7.3	10
67	Reply to the comments on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC. Lung Cancer, 2019, 127, 168.	2.0	2
68	Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. Radiology, 2019, 290, 9-22.	7.3	147
69	Incidental nonneoplastic parenchymal findings in patients undergoing lung resection for mass lesions. Human Pathology, 2019, 86, 93-101.	2.0	19
70	Imaging of Histiocytosis in the Era of Genomic Medicine. Radiographics, 2019, 39, 95-114.	3.3	14
71	DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from programmed death 1 axis inhibition in non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, 9077-9077.	1.6	2
72	Impact of KRAS allele subtypes and concurrent genomic alterations on clinical outcomes to programmed death 1 axis blockade in non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, 9082-9082.	1.6	4

#	Article	IF	Citations
73	Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score â‰¥90%.. Journal of Clinical Oncology, 2019, 37, 9111-9111.	1.6	4
74	Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event. Cancer Immunology Research, 2018, 6, 630-635.	3.4	59
75	An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant toÂDabrafenib Plus Trametinib. Journal of Thoracic Oncology, 2018, 13, e131-e133.	1.1	30
76	<scp>PD</scp>â€1 inhibitorâ€related pneumonitis in lymphoma patients treated with singleâ€agent pembrolizumab therapy. British Journal of Haematology, 2018, 180, 752-755.	2.5	18
77	Histopathology of Interstitial Lung Abnormalities in the Context of Lung Nodule Resections. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 955-958.	5.6	78
78	Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 1019-1029.	3.8	55
79	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. Journal of Clinical Oncology, 2018, 36, 850-858.	1.6	288
80	Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm. European Journal of Radiology, 2018, 109, 68-76.	2.6	8
81	STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discovery, 2018, 8, 822-835.	9.4	1,108
82	Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients. Lung Cancer, 2018, 123, 60-69.	2.0	58
83	Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 5963-5976.	7.0	63
84	Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Clinical Cancer Research, 2017, 23, 204-213.	7.0	73
85	Time-Resolved Quantitative Analysis of the Diaphragms During Tidal Breathing in a Standing Position Using Dynamic Chest Radiography with a Flat Panel Detector System (â€œDynamic X-Ray Phrenicographyâ€). Academic Radiology, 2017, 24, 393-400.	2.5	32
86	Difference in diaphragmatic motion during tidal breathing in a standing position between COPD patients and normal subjects: Time-resolved quantitative evaluation using dynamic chest radiography with flat panel detector system (â€œdynamic X-ray phrenicographyâ€). European Journal of Radiology, 2017, 87, 76-82.	2.6	37
87	Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib. European Journal of Radiology, 2017, 88, 15-20.	2.6	15
88	Interstitial Lung Abnormalities Are Associated with Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 138-141.	5.6	44
89	Programmed Death-1/Programmed Death Ligand-1 Inhibitorâ€“Related Pneumonitis and Radiographic Patterns. Journal of Clinical Oncology, 2017, 35, 1628-1629.	1.6	19
90	Headache in the Setting of Immunotherapy Treatment for Metastatic Melanoma. JAMA Oncology, 2017, 3, 703.	7.1	5

#	Article	IF	Citations
91	Difference in the craniocaudal gradient of the maximum pixel value change rate between chronic obstructive pulmonary disease patients and normal subjects using sub-mGy dynamic chest radiography with a flat panel detector system. European Journal of Radiology, 2017, 92, 37-44.	2.6	13
92	Pleural abnormalities in the Framingham Heart Study: prevalence and CT image features. Occupational and Environmental Medicine, 2017, 74, 756-761.	2.8	11
93	Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. Clinical Cancer Research, 2017, 23, 4671-4679.	7.0	110
94	Risk of Bias and Heterogeneityâ€"Reply. JAMA Oncology, 2017, 3, 858.	7.1	0
95	The MUC5B promoter polymorphism is associated with specific interstitial lung abnormality subtypes. European Respiratory Journal, 2017, 50, 1700537.	6.7	55
96	Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. Radiographics, 2017, 37, 1371-1387.	3.3	56
97	Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models. Clinical Cancer Research, 2017, 23, 6661-6672.	7.0	110
98	Tumor Response Dynamics of Advanced Nonâ€"small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. Clinical Cancer Research, 2017, 23, 5737-5744.	7.0	69
99	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nature Reviews Clinical Oncology, 2017, 14, 655-668.	27.6	787
100	Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. Korean Journal of Radiology, 2017, 18, 42.	3.4	33
101	Drug-Related Pneumonitis in the Era of Precision Cancer Therapy. JCO Precision Oncology, 2017, 1, 1-12.	3.0	35
102	Immune-related tumor response dynamics in melanoma patients (pts) treated with pembrolizumab: Identifying markers for clinical outcome and treatment decisions.. Journal of Clinical Oncology, 2017, 35, 9521-9521.	1.6	1
103	Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight, 2016, 1, e87062.	5.0	340
104	Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. , 2016, 4, 84.		94
105	Low dose chest CT protocol (50 mAs) as a routine protocol for comprehensive assessment of intrathoracic abnormality. European Journal of Radiology Open, 2016, 3, 86-94.	1.6	33
106	Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a â€œcommon languageâ€•for the new arena of cancer treatment. , 2016, 4, 30.		44
107	Pseudoprogression and Measurement Variability. Journal of Clinical Oncology, 2016, 34, 3480-3481.	1.6	12
108	Activity of erlotinib when dosed below the maximum tolerated dose for EGFR â€•mutant lung cancer: Implications for targeted therapy development. Cancer, 2016, 122, 3456-3463.	4.1	15

#	Article	IF	Citations
109	PD-1 Inhibitorâ€“Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clinical Cancer Research, 2016, 22, 6051-6060.	7.0	393
110	Incidence of Programmed Cell Death 1 Inhibitorâ€“Related Pneumonitis in Patients With Advanced Cancer. JAMA Oncology, 2016, 2, 1607.	7.1	600
111	Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1514-1522.	5.6	233
112	Normal thymus in adults: appearance on CT and associations with age, sex, BMI and smoking. European Radiology, 2016, 26, 15-24.	4.5	57
113	Standard-dose vs. low-dose CT protocols in the evaluation of localized lung lesions: Capability for lesion characterizationâ€”iLEAD study. European Journal of Radiology Open, 2016, 3, 67-73.	1.6	30
114	Association Between Interstitial Lung Abnormalities and All-Cause Mortality. JAMA - Journal of the American Medical Association, 2016, 315, 672.	7.4	333
115	Antiâ€“PD-1 Inhibitorâ€“Related Pneumonitis in Nonâ€“Small Cell Lung Cancer. Cancer Immunology Research, 2016, 4, 289-293.	3.4	135
116	Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. Academic Radiology, 2016, 23, 329-336.	2.5	33
117	Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach. European Journal of Cancer, 2016, 53, 163-170.	2.8	45
118	Accuracy and feasibility of estimated tumour volumetry in primary gastric gastrointestinal stromal tumours: validation using semiautomated technique in 127 patients. European Radiology, 2016, 26, 286-295.	4.5	24
119	A comparison of visual and quantitative methods to identify interstitial lung abnormalities. BMC Pulmonary Medicine, 2015, 15, 134.	2.0	39
120	Paraseptal emphysema: Prevalence and distribution on CT and association with interstitial lung abnormalities. European Journal of Radiology, 2015, 84, 1413-1418.	2.6	42
121	Reply to â€œUsefulness of CT in Differentiating Lymphoid Thymic Hyperplasia From True Thymic Hyperplasia: Added Value of Thymic Measurements and CT Attenuationâ€• American Journal of Roentgenology, 2015, 204, W115-W115.	2.2	1
122	Anterior mediastinal masses in the Framingham Heart Study: Prevalence and CT image characteristics. European Journal of Radiology Open, 2015, 2, 26-31.	1.6	46
123	Advanced High-Grade Serous Ovarian Cancer: Frequency and Timing of Thoracic Metastases and the Implications for Chest Imaging Follow-up. Radiology, 2015, 277, 733-740.	7.3	15
124	Interstitial lung abnormalities in treatment-naÃ¯ve advanced non-small-cell lung cancer patients are associated with shorter survival. European Journal of Radiology, 2015, 84, 998-1004.	2.6	54
125	Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. European Journal of Radiology, 2015, 84, 1259-1268.	2.6	105
126	Pulmonary cysts identified on chest CT: are they part of aging change or of clinical significance?. Thorax, 2015, 70, 1156-1162.	5.6	48

#	Article	IF	Citations
127	Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunology Research, 2015, 3, 1185-1192.	3.4	227
128	Antiâ€“PD-1â€“Related Pneumonitis during Cancer Immunotherapy. New England Journal of Medicine, 2015, 373, 288-290.	27.0	339
129	Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in WaldenstrÃ¶m Macroglobulinemia as a Paradigm. Oncologist, 2015, 20, 1077-1083.	3.7	46
130	Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. , 2014, 2, 40.		50
131	Functional Impact of a Spectrum of Interstitial Lung Abnormalities in Rheumatoid Arthritis. Chest, 2014, 146, 41-50.	0.8	78
132	Thymic Measurements in Pathologically Proven Normal Thymus and Thymic Hyperplasia. Academic Radiology, 2014, 21, 733-742.	2.5	14
133	A practical approach to high-resolution CT of diffuse lung disease. European Journal of Radiology, 2014, 83, 6-19.	2.6	57
134	Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer, 2014, 86, 241-246.	2.0	82
135	Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?. , 2014, 2, 17.		77
136	State of the Art: Response Assessment in Lung Cancer in the Era of Genomic Medicine. Radiology, 2014, 271, 6-27.	7.3	114
137	Volumetric tumor growth in advanced nonâ€small cell lung cancer patients with EGFR mutations during EGFRâ€tyrosine kinase inhibitor therapy. Cancer, 2013, 119, 3761-3768.	4.1	40
138	Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer, 2013, 79, 283-288.	2.0	68
139	RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0. American Journal of Roentgenology, 2013, 201, W64-W71.	2.2	39
140	MUC5B Promoter Polymorphism and Interstitial Lung Abnormalities. New England Journal of Medicine, 2013, 368, 2192-2200.	27.0	358
141	Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements. Clinical Cancer Research, 2013, 19, 3936-3943.	7.0	438
142	Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Nonâ€“Small-Cell Lung Cancer Patients Treated with EGFR TKI. Journal of Thoracic Oncology, 2013, 8, 1059-1068.	1.1	48
143	Interstitial Lung Abnormalities and Reduced Exercise Capacity. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 756-762.	5.6	106
144	Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST. American Journal of Roentgenology, 2012, 198, 737-745.	2.2	169

#	Article	IF	Citations
145	Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab. Cancer Imaging, 2012, 12, 225-236.	2.8	50
146	Lung Volumes and Emphysema in Smokers with Interstitial Lung Abnormalities. New England Journal of Medicine, 2011, 364, 897-906.	27.0	468
147	CT Tumor Volume Measurement in Advanced Non-small-cell Lung Cancer. Academic Radiology, 2011, 18, 54-62.	2.5	83
148	Imaging of Lung Cancer in the Era of Molecular Medicine. Academic Radiology, 2011, 18, 424-436.	2.5	37
149	Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know. American Journal of Roentgenology, 2010, 195, 281-289.	2.2	329
150	New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Nonâ€“Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy. American Journal of Roentgenology, 2010, 195, W221-W228.	2.2	182
151	Case 155: Lane-Hamilton Syndrome. Radiology, 2010, 254, 985-988.	7.3	12
152	Volumetric Expiratory HRCT of the Lung: Clinical Applications. Radiologic Clinics of North America, 2010, 48, 177-183.	1.8	16
153	Volumetric Expiratory HRCT of the Lung: Clinical Applications. Thoracic Surgery Clinics, 2010, 20, 121-127.	1.0	4
154	Bronchomalacia in Sarcoidosis. Academic Radiology, 2005, 12, 596-601.	2.5	14